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Introduction & Objective
• Prostate Cancer (PCa) is second most common diagnosed cancer and 
second leading cause of cancer related death in American men1
• Different stage of PCa = Different type of treatment
• Active Surveillance (AS) is an established standard-of-care for low risk (LR) 
PCa à in contrast to unfavorable intermediate (uIR) or high risk PCa, 













1 - Prostate Cancer-American Cancer Society. Prostate Cancer. Available at: http://www.cancer.org/cancer/prostatecancer/. Accessed December 2019.
Introduction & Objective (cont)
However…Utility of AS (vs. AT) for intermediate risk (IR) PCa is less evident4-9
• Prior studies limited - unable to differentiate between AS and Watchful 
Waiting (WW)11
• A recent update to the SEER database for men diagnosed between 2010-
2016 includes the new “watchful waiting” variable which allows for the 
distinction of men enrolled in AS vs WW 12.
Purpose
• We provide the first population-level analysis of AS, WW and AT for 
LR and IR PCa using a recent update in the SEER database
Research Question
• Primary endpoint is to assess whether AS can be utilized as a preferred 
treatment modality for IR PCa in the hopes of improving overall 
survival, cancer-specific survival, and patient quality of life
Hypothesis à AS for IR PCa will not be a preferred treatment 
modality for individuals diagnosed with this stage of disease. 
• ~1:3 men on AS progress to AT within 5 years, which increases with 
disease staging 7-10
• Growing evidence suggests worse AS outcomes with Gleason pattern 4 
disease in long-term data – however statistical power limited 5-10
Research Question & Hypothesis
• Population-Based, Retrospective Study
• Using the SEER database13, men diagnosed with the following, between 2010-
2015, were identified:
• cN0M0 localized Gleason Grade (GG) 1-2




• Patients stratified by (1) GG or (2) NCCN risk categories and initial 
treatment - AT, AS, or WW (using new WW recode (2010+))







Palliative Intent à Non-
Curative
Active Surveillance
Curative Intent à active 
monitoring
Aggressive PSA monitoring, 









• GG2 on AS have worse CSS and OS
• Comparison to GG2 on AT and GG1 on AS or AT
• All LR PCa had similar CSS, however intermediate PCa have worse CSS than AT:
• fIR - starting at 5 year mark
• uIR - earlier than 5 year mark
• fIR and uIR on AS and WW have worse CSS than AT
• WW patients (GG1, GG2, LR, fIR, uIR) have the worst survival outcomes across 
all cohorts (log rank tests p<0.05)
Conclusions & Clinical Impact:
• Improved distinction between WW and AS in the SEER dataset
• Evident GG2 and IR on AS have worse CSS and OSS than comparable cohorts
• With curative intent in mind, we find AS should not be the preferred treatment 
modality for GG2 (IR) PCa
Results & Conclusions
Impact of a positive family history on 
AS outcomes
• FH of PCa
• FH suggestive of a Hereditary Breast-Ovarian
Cancer (HBOC) syndrome
• Prostate, Breast, Ovarian, and Pancreatic cancers
> Outcome: Strong FH suggestive of HBOC à
more aggressive disease in AS patients
Next Steps
• Lynch-Syndrome / DNA-MMR gene mutations
• Endometrial, Uterine, Gastric, UTUC
Future Direction & Follow-Up Study
• Nicholas Bowler (SKMC Class 2021)
• Thenappan Chandrasekar, MD
• Jefferson Urology Department & Sidney Kimmel Cancer Center
• MGH Department of Urology
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